XENOVIEW® 3T coil passes Philips compatibility testing

Core Insights - Polarean Imaging plc has achieved a significant milestone with its FDA-cleared XENOVIEW® 3T Chest Coil, confirming compatibility with Philips' latest 3T MRI platforms, which is expected to enhance clinical reach and adoption of advanced pulmonary imaging [1][2][3] Group 1: Product Development and Integration - The XENOVIEW® 3T Chest Coil has successfully completed compatibility testing with Philips MRI systems, allowing integration starting in early 2026 [2][3] - This development follows the introduction of Xenon MRI compatibility by Philips in 2022, expanding access to advanced pulmonary imaging and supporting functional lung assessment [2][3] - The coil's integration with Philips systems is anticipated to simplify workflow for clinicians, thereby accelerating market penetration and growth opportunities for Polarean [4] Group 2: Market Position and Strategic Goals - The compatibility of the XENOVIEW® 3T Chest Coil with major Philips MRI systems positions Polarean to enhance its market penetration and commercial value globally [3][4] - Polarean aims to optimize lung health and address the unmet medical needs of over 500 million patients suffering from chronic respiratory diseases through innovative imaging solutions [5] - The company is committed to increasing global awareness and access to its XENOVIEW MRI technology platform, which includes a proprietary gas blend and hyperpolarization system [5]